Develops biologics for immune modulation and cancer immunotherapy, focusing on novel approaches to enhance patient outcomes.
HCW Biologics Inc. is a biopharmaceutical company in the preclinical stage, specializing in the discovery and development of innovative immunotherapies targeting chronic, low-grade inflammation, and age-related diseases.
The company's pipeline is anchored by HCW9218, an injectable immunotherapeutic designed for pancreatic, ovarian, breast, prostate, colorectal cancers, and pulmonary fibrosis. HCW Biologics also focuses on HCW9302, aimed at autoimmune conditions like alopecia areata and metabolic diseases. Additionally, the company is advancing HCW9201, a cell-based therapy currently in Phase II clinical trials for relapsed/refractory acute myeloid leukemia, and HCW9206 for acute myeloid leukemia treatment.
Founded in 2018 and headquartered in Miramar, Florida, HCW Biologics Inc. is committed to pioneering therapies that address significant medical needs. The company's innovative approach and clinical advancements underscore its dedication to transforming treatment options for complex diseases.